Enlarge / The director of Germany’s Nationwide Reference Centre for Invasive Fungal Infections holds a petri dish containing the yeast Candida auris in a laboratory at Wuerzburg College. (credit score: Getty | Nicolas Armer)
A lethal, drug-resistant fungus rising within the US gained floor quicker and picked up but extra drug resistance amid the COVID-19 pandemic, researchers on the Facilities for Illness Management and Prevention reported Monday.
The yeast Candida auris has been thought of an “pressing risk”—the CDC’s highest degree of concern—because it was first reported within the US in 2016. The yeast lurks in well being care settings and preys upon weak sufferers, inflicting invasive infections with a fatality fee of between 30 to 60 p.c.
In 2019, earlier than the pandemic started, 17 states and Washington, DC, reported a complete of 476 scientific instances. However in 2020, eight further states reported instances for the primary time, with the nationwide scientific case depend leaping 59 p.c to 756. In 2021, 28 states had been affected, with the scientific case depend practically doubling to 1,471. Asymptomatic instances detected by means of affected person screening additionally jumped amid the pandemic, tripling from 1,310 instances in 2020 to 4,041 instances in 2021. The info appeared Monday within the Annals of Inner Medication.
Learn 5 remaining paragraphs | Feedback
